High-Impact Form 4 Intelligence
Real-time SEC insider trading data with advanced filtering. Free beta.
Total Buys (Filtered)
$0
$0
Total Sells (Filtered)
$2.7M
$2,660,076
| Ticker | Company | Reporting Owner | Date | Value (USD) | Type | Form 4 |
|---|---|---|---|---|---|---|
|
TVTX
S
Travere Therapeutics, Inc.
Calvin Sandra
• Officer • SVP, CHIEF ACCOUNTING OFFICER
Sell to Cover
2026-02-03
$139,176
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • SVP, CHIEF ACCOUNTING OFFICER
Sell to Cover
|
2026-02-03 | $139,176 | S | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Calvin Sandra
• Officer • SVP, CHIEF ACCOUNTING OFFICER
10b5-1 Sell
2025-12-15
$104,760
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • SVP, CHIEF ACCOUNTING OFFICER
10b5-1 Sell
|
2025-12-15 | $104,760 | S | Form 4 |
|
TVTX
M
Travere Therapeutics, Inc.
Calvin Sandra
• Officer • SVP, CHIEF ACCOUNTING OFFICER
Other
2025-11-04
$1,471,212Largex5
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • SVP, CHIEF ACCOUNTING OFFICER
Other
|
2025-11-04 | $1,471,212Largex5 | M | Form 4 |
|
TVTX
S
Travere Therapeutics, Inc.
Calvin Sandra
• Officer • SVP, CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -58.0%
2025-11-04
$2,416,140Large
|
||||||
| TVTX |
Travere Therapeutics, Inc.
|
Officer • SVP, CHIEF ACCOUNTING OFFICER
10b5-1 SellΔOwn -58.0%
|
2025-11-04 | $2,416,140Large | S | Form 4 |